Sensitization of Therapeutic Resistant Pancreatic Cancer by Cancer Cell-Specific Drug Delivery
Abstract
In the second year of this three-year project, we have completed most of the tasks following the timeline of our Statement of Work, although the COVID-19 pandemic has severely affected progress of the project by interrupting the proposed animal studies. We have partially characterized the two new pancreatic cancer cell lines by verifying their tumorigenicity in athymic mice, and confirmed dose-dependent killing of all the six pancreatic cancer cell lines by HMCD-SIM, all in doses below 12.5 M. In the first test, HMCD-SIM inhibited UN-KPC-960 intrasplenic tumor growth and prolonged 129 mice host survival. Modified experimental protocol will be used in repeated studies to consolidate effect of the conjugate in immune intact mice. In GASP-1 ELISA assays with a wide spectrum of patient samples, it is revealed that substantial amount of GASP-1 was detected in pancreatitis, indicating that the GASP-1 biomarker lacks tumor cell-specificity. These successes greatly help the research project focus on the effectiveness of HMCD-SIM as an effective anti-tumor agent in the third year.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2020
- Accession Number
- AD1117732
Entities
People
- Leland W. Chung
- Stephen J Pandol
Organizations
- Cedars-Sinai Medical Center